Objectives of Study:
|
Cholestatic liver disease in infants is a common disease in infancy. It is a liver disease caused by multiple etiologies such as infection, genetic, metabolic, or developmental disorders.Its clinical features mainly include hyperbinding bilirubinemia, light fecal color and dark urine, with or without hepatomegaly, abnormal liver function and so on.The incidence of ICH in live births is 1:2500.Cholestatic liver fibrosis refers to chronic inflammation in the liver caused by persistent cholestasis, which damages bile duct cells and liver cells, induces bile duct reaction, and activates myofibroblast (MFB) through various regulatory factors, causing excessive deposition of ECM, and thus leading to liver fibrosis.ICH occurred cholestasis liver fibrosis main groups, 6 months the incidence of hepatic fibrosis in children with congenital biliary atresia ICH, about 45.1%, cholestasis, the toxicity of MFB, bile acid and bile duct reaction to promote progress in the direction of the fibrosis disease, for example early if left untreated, cholestasis will lead to a variety of cell damage, continuous progress to liver fibrosis, finally the irreversibility of end-stage liver cirrhosis or liver failure lesions, to family and society brings serious burden.Therefore, anti-fibrosis therapy for the proliferation and degradation of fibrous tissue is particularly important for the prognosis, and blocking or delaying the progression of liver fibrosis or even completely reversing liver fibrosis has become an urgent clinical problem to be solved.
|
Description for medicine or protocol of treatment in detail:
|
Cholagogic mixture formula particles provided by the CRC san-jiu pharmaceutical co., limited: herba artemisiae 30 g (batch number: 2006003 c, medicine to 1:10), 20 g forsythia (batch number: 1911001 s, medicine than 1:10), 5 g cooked rhubarb (batch number: 1912001 s, medicine than 1:6), red paeony root, 20 g (batch number: 2008010 c, medicine to 1:5), 7 g cassia twig (batch number: 1911006 c, medicine to 1:12), atractylodes 10 g (batch number: 2005003 c, medicine to 1:5), 10 g turtle shell (batch number:1907001S, medicine ratio 1:10), licorice 7g (lot number: 2005008C, medicine ratio 1:6).Ursodeoxycholic acid capsule (Losan Pharma GmbH, specification: 250mg, lot number: 16G13392L)
2.7.2 Treatment methods
Etiological treatment: Children with NICCD were fed lactose free and/or medium chain fatty acid formula.Cytomegalovirus infection with ganciclovir standard antiviral therapy;Sepsis was treated with anti-infective therapy;Avoid lactose and galactose, etc.
Western medicine treatment: The observation group and the control group were given ursodeoxycholic acid (10-30mg/kg/d, orally taken twice) for 6 weeks after 14 days of anti-fibrosis treatment in the hospital.
TCM treatment: According to TCM syndromes, the observation group was divided into dampness-heat fumigation syndrome, cold-dampness block syndrome, stagnant accumulation and yellowing syndrome, Lidang Mixture as the main prescription, dampness-heat fumigation syndrome removing cassia twig and gardenia, cold-dampness block syndrome removing mature rhubarb and dried ginger or cinnamon, stagnant accumulation and yellowing syndrome reusing red peony root and adding polygonum cuspidate.One tablet per day, 100ml per day, administered orally twice for 6 weeks.
|